{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-043170","form_type":"8-K","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2023-11-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.149785+00:00","generated_at":"2026-06-07T20:03:24.809397+00:00","sec_items":["3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ZyVersa Therapeutics approves 1-for-35 reverse stock split and increases authorized shares to 251M","bullets":["Reverse split 1:35 effective Dec 4, 2023 at 4:01 pm ET; adjusted trading begins Dec 5 under ZVSA.","Authorized common shares increased from 110M to 250M; total capital stock from 111M to 251M.","Split intended to meet Nasdaq's $1.00 minimum bid price requirement for continued listing.","No fractional shares will be issued; holders will receive rounding to nearest whole share.","Proportional adjustments to equity awards, warrants, and convertible securities."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-043170","json":"https://secwatch.observer/filing/0001493152-23-043170.json","markdown":"https://secwatch.observer/filing/0001493152-23-043170.md","text":"https://secwatch.observer/filing/0001493152-23-043170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223043170/0001493152-23-043170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223043170/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:03:24.809397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f4d0b2304ac118f4897391a338228583929a8e8","claim":"ZyVersa Therapeutics, Inc.: Certificate of amendment to effect a 1-for-35 reverse stock split and increase authorized capital stock from 111,000,000 to 251,000,000 shares (effective 2023-12-04).","evidence_excerpt":"On November 30, 2023, ZyVersa Therapeutics, Inc. (the “Company”) filed a certificate of amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware relating to a 1-for-35 reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock (“Common Stock”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223043170/0001493152-23-043170-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-12-04"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}